29C1 Stock Overview
Provides pharmacy services to seniors homes and other congregate care settings in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CareRx Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.39 |
| 52 Week High | CA$1.63 |
| 52 Week Low | CA$0.75 |
| Beta | 0.91 |
| 1 Month Change | -4.14% |
| 3 Month Change | 34.95% |
| 1 Year Change | -7.95% |
| 3 Year Change | -67.97% |
| 5 Year Change | -57.62% |
| Change since IPO | -81.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 29C1 | DE Consumer Retailing | DE Market | |
|---|---|---|---|
| 7D | 3.7% | -3.2% | -0.3% |
| 1Y | -7.9% | -38.9% | 4.5% |
Return vs Industry: 29C1 exceeded the German Consumer Retailing industry which returned -39.1% over the past year.
Return vs Market: 29C1 underperformed the German Market which returned 4.3% over the past year.
Price Volatility
| 29C1 volatility | |
|---|---|
| 29C1 Average Weekly Movement | 8.3% |
| Consumer Retailing Industry Average Movement | 6.7% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 29C1's share price has been volatile over the past 3 months.
Volatility Over Time: 29C1's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,559 | Puneet Khanna | www.carerx.ca |
CareRx Corporation, together with its subsidiaries, provides pharmacy services to seniors homes and other congregate care settings in Canada. The company offers medication management, technology, and program solutions. It serves long-term care homes, retirement homes, assisted living facilities, and group homes.
CareRx Corporation Fundamentals Summary
| 29C1 fundamental statistics | |
|---|---|
| Market cap | €86.21m |
| Earnings (TTM) | -€2.55m |
| Revenue (TTM) | €249.46m |
0.3x
P/S Ratio-33.8x
P/E RatioIs 29C1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 29C1 income statement (TTM) | |
|---|---|
| Revenue | CA$369.07m |
| Cost of Revenue | CA$263.53m |
| Gross Profit | CA$105.54m |
| Other Expenses | CA$109.32m |
| Earnings | -CA$3.77m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.063 |
| Gross Margin | 28.60% |
| Net Profit Margin | -1.02% |
| Debt/Equity Ratio | 81.4% |
How did 29C1 perform over the long term?
See historical performance and comparison